The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.